Plasma filtration for the controlled removal of liposomal therapeutics - From the apheretic site of view
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F17%3A10365938" target="_blank" >RIV/00179906:_____/17:10365938 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11150/17:10365938
Result on the web
<a href="http://www.sciencedirect.com/science/article/pii/S1567568817300648?via%3Dihub" target="_blank" >http://www.sciencedirect.com/science/article/pii/S1567568817300648?via%3Dihub</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.022" target="_blank" >10.1016/j.atherosclerosissup.2017.05.022</a>
Alternative languages
Result language
angličtina
Original language name
Plasma filtration for the controlled removal of liposomal therapeutics - From the apheretic site of view
Original language description
Introduction: Nanoparticle-based drug delivery systems can overcome the dose-limited toxicity of cytostatics. Pegylated doxorubicin-containing liposomes (PLD) are able to reduce cardiotoxicity. PLD quickly (in 2 days) attains therapeutic concentration in tumorous tissue (kinetic targeting), while its distribution in normal tissue, which is a cause of mucocutaneous toxicity (MCT), is delayed. We examined PLD extracorporeal removal effectivity, using plasma filtration (PF) to determine whether the drug could be withheld prior to its organ distribution responsible for MCT toxicity. Methods: Nine patients suffering from platinum-resistant ovarian cancer were treated with a infusion of 50 mg/m(2) of PLD/cycle - for four cycles q4w. Over 44 (46)-47 (49) hours postinfusion, the patients (14 cycles in total) underwent PF using the cascade method. Doxorubicin blood concentration was monitored by the HPLC method during 116 h. Individual pharmacokinetic parameters of doxorubicin were estimated. Results: Over 44 (46) -47 (49) hours postinfusion, a single one-volume plasma filtration removed 35 (22-45)% of the remaining doxorubicin amount in the body. Symptoms of MCT - PPE-like syndrome (grade 3) appeared in one patient. Only one adverse reaction (1/14-7%) - short-term malaise and nausea - was reported as being related to PF. Conclusion: PF does remove a clinically important amount of doxorubicin in a kinetic targeting approach, which can be a useful tool for the increased efficacy and tolerability of therapy with PLD. There were no serious signs of drug toxicity and/or PF-related adverse events.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
<a href="/en/project/NV16-30366A" target="_blank" >NV16-30366A: Liposoms (drug delivery systems) in kinetically guided therapy of ovarian platinum-resistent carcinoma with doxorubicin using plasmafiltration.</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Atherosclerosis, Supplements
ISSN
1567-5688
e-ISSN
—
Volume of the periodical
30
Issue of the periodical within the volume
November
Country of publishing house
IE - IRELAND
Number of pages
8
Pages from-to
286-293
UT code for WoS article
000415625000042
EID of the result in the Scopus database
2-s2.0-85032454029